Factors affecting defining the quality and functionality of excipients used in the manufacture of dry powder inhaler products

Drug Development and Industrial Pharmacy

Volumn 34, Issue 9, 2008, Pages 966-973

  Edge, Stephen ^a   Mueller, Stefan ^a   Price, Robert ^b   Shur, Jagdeep ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b University of Bath   (United Kingdom)

Author keywords

Dry powder inhaler; Excipient; Functionality; Lactose; Quality

Indexed keywords

EXCIPIENT; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL FUMARATE; IPRATROPIUM BROMIDE; LACTOSE; MAGNESIUM STEARATE; MOMETASONE FUROATE; RECOMBINANT HUMAN INSULIN; TERBUTALINE;

DRUG FORMULATION; DRUG MANUFACTURE; DRUG QUALITY; DRY POWDER; POWDER INHALER; REVIEW;

EXCIPIENTS; NEBULIZERS AND VAPORIZERS; POWDERS;

EID: 52149109293     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040802192814     Document Type: Review

References (23)

1. Amidon, G. E., Peck, G. E., Block, L. H., Moreton, R. C., Katdare, A., Lafaver, R., & Sheehan, C. (2007). Proposed new USP general information chapter, excipient performance 〈1059〉. Pharmacopoeial Forum, 33, 1311-1323.
2. Begat, P., Morton, D. A. V., Staniforth, J. N., & Price, R. (2004). The cohesive-adhesive balances in dry powder inhaler formulations I: Direct quantification by atomic force microscopy. Pharm. Res., 21, 1591-1597.
3. CDER. (1998). Guidance for industry: Metered dose inhaler (MDI) and dry powder inhaler (DPI) drug products (draft). Rockville, MD: United States Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Retrieved September 8, 2008, from http://www.fda.gov/cder/guidance/2180dft.htm
4. Chow, A. H., Tong, H. H., Chattopadhyay, P., & Shekunov, B. Y. (2007). Particle engineering for pulmonary drug delivery. Pharm. Res., 24, 411-437.
5. EMEA. (2006). Committee for Medicinal Products for Human Use. Guidance on the pharmaceutical quality of inhalation and nasal products. Retrieved September 8, 2008, from www.emea.europa.eu/pdfs/human/qwp/4931305en.pdf. London, 12 June 2006.
6. European Pharmacopoeia. (2008). (6th ed., Suppl. 2). Strasbourg, France: Council of Europe, Retrieved September 8, 2008, from http://online.pheur.org
7. Hickey, A. J., Mansour, H. M., Telko, M. J., Xu, Z., Smyth, H. D., Mulder, T., McLean, R., Langridge, J., & Papadopoulos, D. (2007). Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics. J. Pharm. Sci., 96, 1282-1301.
8. ICH. (2006). International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use Quality 8 (International conference on harmonization, 15, chemin Louis-Dunant, P.O. Box 195, 1211 Geneva 20, Switzerland, May 2006), Retrieved September 8, 2008, from http://www.ich.org/LOB/media/MEDIA1707.pdf
9. Kaerger, S. K., Price, R., Young, P. M., Edge, S., & Tobyn, M. J. (2006). Carriers for DPIs: Formulation and regulatory challenges. Pharm. Tech. Europe, 18, 25-30.
10. Kieckbusch, T., Eskandar, F., Lejeune, M., Edge, S., Ziegler, D., & Dalvi, M. (2007, December 12-14). Low mass powder dosing system - from laboratory scale to pilot scale. Proceedings of Drug Delivery to the Lungs XVIII, Edinburgh, UK.
11. Morisset, M., Moneret-Vautrin, D., Commun, N., Schuller, A., & Kanny, G. (2006). Allergy to cow milk proteins contaminating lactose, common excipient of dry powder inhalers for asthma. J. Allergy Clin. Immunol., 117(2, Suppl. 1), S95.
12. Newell, H. E., Buckton, G., Butler, D. A., Thielmann, F., & Williams, D. R. (2001). The use of inverse phase gas chromatography to study the change of surface energy of amorphous lactose as a function of relative humidity and the processes of collapse and crystallization. Int. J. Pharm., 217, 45-56.
13. Nowak-Wegrzyn, A., Shapiro, G. G., Beyer, K., Ludmila Bardina, L., & Sampson, H. A. (2004). Contamination of dry powder inhalers for asthma with milk proteins containing lactose. J. Allergy Clin. Immunol., 113, 558-560.
14. Planinšek, O., Trojak, A., & Srcic, S. (2001). The dispersive component of the surface free energy of powders assessed using inverse gas chromatography and contact angle measurements. Int. J. Pharm., 221, 211-217.
15. Price, R., Young, P. M., Edge, S., & Staniforth, J. N. (2002). The influence of relative humidity on particulate interactions in carrier-based dry powder inhaler formulations. Int. J. Pharm., 246, 47-59.
16. Rowe, R. C., Sheskey, P. J., & Owen, S. C. (Eds.). (2005). Handbook of pharmaceutical excipients (5th ed.). London: Pharmaceutical Press.
17. Rowley, G., & Mackin, L. A. (2003). The effect of moisture sorption on electrostatic charging of selected pharmaceutical excipient powders. Powder Technol., 135-136, 50-58.
18. Sethuraman, V. V., & Hickey, A. J. (2002). Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug. AAPS Pharm-SciTech., 3(4), E28, Retrieved September 8, 2008, from http://www.aapspharmscitech.org.
19. Swaminathan, V., Cobb, J., & Saracovan, I. (2006). Measurement of the surface energy of lubricated pharmaceutical powders by inverse gas chromatography. Int. J. Pharm., 312, 158-165.
20. Telko, M. J., & Hickey, A. J. (2005). Dry powder inhaler formulation. Respir. Care, 50, 1209-1227.
21. Telko, M. J., & Hickey, A. J. (2007). Critical assessment of inverse gas chromatography as means of assessing surface free energy and acid-base interaction of pharmaceutical powders. J. Pharm. Sci., 96, 2647-2654.
22. Ticehurst, M. D., York, P., Rowe, R. C., & Dwivedi, S. K. (1996). Characterisation of the surface properties of alpha-lactose monohydrate with inverse gas chromatography, used to detect batch variation. Int. J. Pharm., 141, 93-99.
23. United States Pharmacopoeia. (31st Rev. ed.), The National Formulary (26th Rev. ed.) (Suppl. 1) (2008). Rockville, MD: The United States Pharmacopoeial Convention, Inc, Retrieved September 8, 2008, from www.uspnf.com.